Spots Global Cancer Trial Database for An Open Label Prostate Cancer Study in Japanese Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open Label Prostate Cancer Study in Japanese Patients
Official Title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT01351688
Conditions
Interventions
Study Description
Brief Summary: The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action. In this study, AZD3514 will be administered to Japanese patients with metastatic castration resistant prostate cancer.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Research Site, Sagamihara, Kanagawa, Japan
Research Site, Sunto-gun, Shizuoka, Japan
Contact Details
Name: Glen Clack, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Takefumi Sato, MD
Affiliation: Kitasato University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
